Comparison of Dual Monoclonal Antibody Therapies for COVID-19 Evolution: A Multicentric Retrospective Study.
Humans
Retrospective Studies
Male
Antibodies, Monoclonal, Humanized
/ therapeutic use
Female
Middle Aged
SARS-CoV-2
/ immunology
Aged
COVID-19 Drug Treatment
Spike Glycoprotein, Coronavirus
/ immunology
Antibodies, Monoclonal
/ therapeutic use
Antibodies, Neutralizing
/ therapeutic use
COVID-19
/ immunology
Hospitalization
Antiviral Agents
/ therapeutic use
Adult
Treatment Outcome
Aged, 80 and over
Drug Combinations
COVID-19
SARS-CoV-2
immune escape mutation
monoclonal antibody therapy
spike gene
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
29 Sep 2024
29 Sep 2024
Historique:
received:
19
08
2024
revised:
14
09
2024
accepted:
24
09
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
26
10
2024
Statut:
epublish
Résumé
Neutralizing antibodies targeting the SARS-CoV-2 Spike protein reduce COVID-19-related risk of hospitalization, particularly in high-risk individuals. The COCOPREV-R study aimed to evaluate and compare clinical outcomes in high-risk SARS-CoV-2 patients treated with dual monoclonal antibody therapies and to identify associated virological factors. The COCOPREV-R study retrospectively collected real-world data from high-risk patients receiving Bamlanivimab/Etesevimab or Casirivimab/Imdevimab dual monoclonal antibody therapies (22 February 2021 to 15 June 2021). The study included 1004 patients with COVID-19, of whom 691 received Bamlanivimab/Etesevimab and 313 received Casirivimab/Imdevimab. The alpha variant represented 90.1% of those for whom data were available. The risk of hospitalization within 30 days was lower with Bamlanivimab/Etesevimab (12.7%, CI 95% [9.9-16.3%]) compared to Casirivimab/Imdevimab (28.4%, CI 95% [22.7-35.1%) ( A higher rate of hospitalization was seen with Casirivimab/Imdevimab (RONAPREVE
Sections du résumé
BACKGROUND
BACKGROUND
Neutralizing antibodies targeting the SARS-CoV-2 Spike protein reduce COVID-19-related risk of hospitalization, particularly in high-risk individuals. The COCOPREV-R study aimed to evaluate and compare clinical outcomes in high-risk SARS-CoV-2 patients treated with dual monoclonal antibody therapies and to identify associated virological factors.
METHODS
METHODS
The COCOPREV-R study retrospectively collected real-world data from high-risk patients receiving Bamlanivimab/Etesevimab or Casirivimab/Imdevimab dual monoclonal antibody therapies (22 February 2021 to 15 June 2021).
RESULTS
RESULTS
The study included 1004 patients with COVID-19, of whom 691 received Bamlanivimab/Etesevimab and 313 received Casirivimab/Imdevimab. The alpha variant represented 90.1% of those for whom data were available. The risk of hospitalization within 30 days was lower with Bamlanivimab/Etesevimab (12.7%, CI 95% [9.9-16.3%]) compared to Casirivimab/Imdevimab (28.4%, CI 95% [22.7-35.1%) (
CONCLUSIONS
CONCLUSIONS
A higher rate of hospitalization was seen with Casirivimab/Imdevimab (RONAPREVE
Identifiants
pubmed: 39459877
pii: v16101542
doi: 10.3390/v16101542
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Spike Glycoprotein, Coronavirus
0
casirivimab and imdevimab drug combination
0
Antibodies, Monoclonal
0
Antibodies, Neutralizing
0
etesevimab
N7Q9NLF11I
bamlanivimab and etesevimab drug combination
0
bamlanivimab
45I6OFJ8QH
spike protein, SARS-CoV-2
0
Antiviral Agents
0
casirivimab
J0FI6WE1QN
Drug Combinations
0
Types de publication
Journal Article
Multicenter Study
Comparative Study
Langues
eng
Sous-ensembles de citation
IM